These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1987495

  • 1. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
    Basso D, Panozzo MP, Fabris C, Meggiato T, Faggian D, Fogar P, Scalon P, Del Favero G, Plebani M, Burlina A.
    Oncology; 1991; 48(1):22-5. PubMed ID: 1987495
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M, Ubalducci GM, Cipolla A, Panella MA, Ligabue A.
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [Abstract] [Full Text] [Related]

  • 5. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
    Basso D, Fabris C, Del Favero G, Piccoli A, Angonese C, Pasquali C, Castoro C, Plebani M, Leandro G, Burlina A.
    Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
    Pålsson B, Masson P, Andrén-Sandberg A.
    Scand J Gastroenterol; 1993 Nov; 28(11):981-7. PubMed ID: 8284635
    [Abstract] [Full Text] [Related]

  • 10. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
    Plebani M, Basso D, Navaglia F, D'Angeli F, Panozzo MP, Del Giudice G, Battistel M, Meggiato T, Del Favero G.
    Oncology; 1995 Nov; 52(1):19-23. PubMed ID: 7800337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M, Basso D, Del Favero G, Ferrara C, Meggiato T, Fogar P, Mangano F, Ricciardi G, Burlina A.
    Oncology; 1993 Nov; 50(6):436-40. PubMed ID: 8233283
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992 Nov; 12(5):1687-93. PubMed ID: 1332581
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Diagnostic value of radioimmunological analysis of CA-19-9 in the blood serum in cancer of the pancreas].
    Putseva NM, Chebotareva ED, Chernyĭ VA, Tashchiev RK.
    Klin Khir (1962); 1989 Nov; (11):15-7. PubMed ID: 2625847
    [Abstract] [Full Text] [Related]

  • 19. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
    Kawa S, Tokoo M, Hasebe O, Hayashi K, Imai H, Oguchi H, Kiyosawa K, Furuta S, Homma T.
    Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
    [Abstract] [Full Text] [Related]

  • 20. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.